Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • hollystephens723
    Member
    • Dec 2018
    • 36

    #1

    PrecisionFDA FDA Open Data Challenge Update

    For those interested in participating in the precisionFDA Gaining New Insights by Detecting Adverse Event Anomalies Using FDA Open Data Challenge, you have 10-days days left to complete your submission. Selected participants will be invited to participate in a panel at the Modernizing FDA’s Data Strategy public meeting. Final submissions are due on February 28th, and providing code is no longer required for a valid entry. Additionally, new guidance is available on the challenge site including updated evaluation criteria and anomaly examples.


    If you are interested in learning more about how FDA is modernizing its data strategy, please attend the Modernizing FDA’s Data Strategy public meeting on March 27th. The meeting will also be streamed virtually for those who don’t live in the DC area!

    If you have any questions about the challenge, please feel free to post them in this thread and we will respond as quickly as possible.
  • hollystephens723
    Member
    • Dec 2018
    • 36

    #2
    We are pleased to announce that the Journal of the American Medical Informatics Association (JAMIA) supports the submission of a paper describing the precisionFDA Gaining New Insights by Detecting Adverse Event Anomalies Using FDA Open Data challenge and broadly applicable insights that emerge from it. Publication in JAMIA will be contingent on a standard evaluation process including editorial assessment and peer review.

    As a friendly reminder for those of you participating in the challenge you have one week left before final submissions are due on February 28th at https://go.usa.gov/xdEW2.

    If you have any questions about the challenge, please feel free to post them in this thread and we will respond as quickly as possible.

    Comment

    Latest Articles

    Collapse

    • SEQadmin2
      Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
      by SEQadmin2



      CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

      Despite this, “CRISPR helped turn genome editing from a specialized technique into
      ...
      07-31-2026, 11:01 AM
    • SEQadmin2
      Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
      by SEQadmin2


      Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

      The systematic characterization of the human proteome has
      ...
      07-20-2026, 11:48 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, Yesterday, 10:35 AM
    0 responses
    9 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 08-06-2026, 07:41 AM
    0 responses
    27 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 08-03-2026, 10:13 AM
    0 responses
    46 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-31-2026, 02:55 AM
    0 responses
    48 views
    0 reactions
    Last Post SEQadmin2  
    Working...